Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1995-05-10
1998-06-09
Kight, John
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
536 2613, A61K 3170, C07H 1922
Patent
active
057634190
ABSTRACT:
The compound 8-chloroadenosine 3',5'-cyclic phosphate and its pharmaceutically acceptable salts are used to treat malignant tumors in afflicted hosts.
REFERENCES:
patent: 4198489 (1988-05-01), Cho-Chung
Cho-Chung(II), "Site Selective 8-Chloro-Cyclic Adenosine 3', 5'-Monophosphate as a Biologic Modulator of Cancer: Restoration of Normal Control Mechanisms," J. Nat. Cancer Inst. USA, 81(13), 982-987 (1989).
Avery et al., "Treatment of Murine and Human Neoplasms In Vivo with the Site-Selective cAMP Analog, 8-C1-cAMP," Proc. Am. Assoc. Cancer Res., Abstr. 1408, vol. 29, 354 (1988).
Parandoosh et al., "Diaclglycerol (DAG) Mass Measurement in Tumor Cells Treated with 8-Chloro and 8-Amino cAMP," Proc. Am. Assoc. Cancer Res., Abstr. 1409, vol. 29, 354 (1988); (formerly cited as Avery et al.).
Rubalcava et al., "8-Chloro and 8-Amino cAMP Translocate Protein Kinase C From Plasma Membrane to Cytosol In Cancer Calls," Proc. Am. Assoc. Cancer Res., Abstr. 1426, vol. 29, 358 (1988).
Ally et al., "Suppression of the Growth in Athymic Mice of Human Lung Carcinomas by 8-C1-cAMP is Associated With Differential Regulation of the cAMP Receptor Proteins and c-ras Proto-oncogene," Proc. Am. Assoc. Cancer Res., Abstr. 223, vol. 29, 56 (1988).
Katsaros et al., "Transcriptional Activation of the R.sup.II cAMP Receptor Protein and cras Proto-oncogene in the Growth Inhibition of Human Colon Cancer Cell Line Treated with 8-C1-cAMP," Proc. Am. Assoc. Cancer Res., Abstr. 231, vol. 29, 58 (1988).
Katsaros et al., "Site-Selective Cyclic AMP Analogs Provide a New Approach Control of Cancer Cell Growth," FEBS Letters, 223(1), 97-103 (1987).
Cho-Chung et al.(I), "Site Selective cAMP Analogs are Cytostatic and Differentiating Agents for a Spectrum of Human Cancer Cell Lines: Potential for Application to Chemotherapy," Proc. Am. Soc. Clin. Oncology, 6, Abstr. 62, p. 17, 1987.
Tagliaferri et al.(I), "Reverse Transformation of Harvey Murine Sarcoma Virus-transformed NIH/3T3 Cells by Site-Selective Cyclic AMP Analogs," J. Biol. Chem., 263(1), 409-416 (Jan. 15, 1988(.
Tagliaferri et al.(II), "Synergistic Inhibition of Growth of Breast and Colon Human Cancer Cell Lines by Site-Selective Cyclic AMP Analogues," Cancer Res., 48, 1642-1650 (Mar. 15, 1988).
Tortora et al.(I), "Site-Selective cAMP Analogs at Micromolar Concentrations Induce Growth Arrest and Differentiation of Acute Promyelocytic, Chronic Myelocytic, and Acute Lymphocytic Human Leukemia Cell Lines,"Blood 71(1), 230-233 (Jan. 1988).
Houghton et al., "The Suitability and Use of Human Tumor Xenografts," Chapter 42 in Rodent Tumor Models in Experimental Cancer Therapy, reports of a meeting held in Oct. 1984, Kallman ed., 1987, Pergamon Press, New York, pp. 199-204.
Steel, "How Well Do Xengrafts Maintain the Therapeutic Response Characteristics of the Source Tumor in the Donor Patient?" Chapter 43 in Rodent Tumor Models in Experimental Cancer Therapy, reports of a meeting held in Oct. 1984, Kallman ed., 1987, Pergamon Press, New York, pp. 205-208.
Kallinowski et al., "Blood Flow and Oxygen Consumption of Primary and Xenotransplanted Human Mammary Carcinomas," Chapter 45 in Rodent Tumor Models in Experimental Cancer Therapy, reports of a meeting held in Oct. 1984, Kallman ed., 1987, Pergamon Press, New York, pp. 214-217.
Ovejera, "The Use of Human Tumor Xenografts in Large-Scale Drug Screening," Chapter 46 in Rodent Tumor Models in Experimental Cancer Therapy, reports of a meeting held in Oct. 1984, Kallman ed., 1987, Pergamon Press, New York, pp. 218-220.
Shorthouse et al., "The Human Tumour Xenograft -A Valid Model in Experimental Chemotherapy?" Br. J. Surg., 67, 715-722 (1980).
Chahinian et al., "Usefulness of the Nude Mouse in Mesothelioma Based on a Direct Patient-Xenograft Comparison," Cancer, 68, 558-560 (1991).
In Vivo Cancer Models, 1976-1982, U. S. National Institutes of Health Publication No. 84-2635, Feb. 1984, Bethesda, MD.
Beardsley, "Trends in Cancer Epidemiology -A War Not Won," Scientific American, 270(1), 130-138 (1994).
Rohlff et al., "8-C1-cAMP Induces Truncation and Down-regulation of the RI.sub..alpha. Subunit and Up-regulation of the RII.sub..beta. Subunit of cAMP-dependent Protein Kinase Leading to Type II Holoenzyme-dependent Growth Inhibition and Differentiation of HL-60 Leukemia Cells," J. Biol. Chem., 268(8), 5774-5782 (Mar. 1993).
Cho-Chung et al. (II), "Suppression of Malignancy Targeting the Intracellular Signal Transducing Proteins of cAMP: The Use of Site-Selective cAMP Analogs, Antisense Strategy, and Gene Transfer," Life Sciences, 48(12), 1123-1132 (1991).
Cho-Chung et al. (III), "Regulatory Subunit of cAMP-Dependent Protein Kinase as a Target for Chemotherapy of Cancer and Other Cellular Dysfunctional-Related Diseases," Pharmacological Therapy, 60, 265-288 (1993).
Pinto et al., "Inhibition of the Self-Renewal Capacity of Blast Progenitors from Acute Myeloblastic Leukemia Patients by Site-Selective 8-Chloroadenosine 3', 5'-Cyalic Monophosphate," Proc. Nat. Acad. Sci. USA, 89, 8884-8888 (Oct. 1992).
Tortora et al.(II), "Differentiation of HL-60 Leukemia by Type I Regulatory Subunit Antisense Oligodeoxynucleotide of cAMP-Dependent Protein Kinase," Proc. Nat. Acad. Sci. USA, 88, 2011-2015 (Mar. 1991).
Cho-Chung Yoon Sang
Robins, deceased Roland K.
Crane L. Eric
ICN Pharmaceuticals
Kight John
LandOfFree
Treatment of malignant tumors with 8-chloroadenosine 3',5'-cycli does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of malignant tumors with 8-chloroadenosine 3',5'-cycli, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of malignant tumors with 8-chloroadenosine 3',5'-cycli will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2199223